Meeting the challenges of retention and enrollment of study participants in clinical trials during the COVID-19 pandemic from the study leadership perspective: Experience from the Zoster Eye Disease Study (ZEDS)
Cohen, Elisabeth J
Hochman, Judith S
Troxel, Andrea B
Jeng, Bennie H
JournalContemporary Clinical Trials Communications
MetadataShow full item record
AbstractPurpose: To describe steps taken that enabled a high rate of retention and early resumption of enrollment in the Zoster Eye Disease Study (ZEDS), a randomized controlled trial funded by the National Eye Institute, during the first 13 months (3/1/2020-3/31/2021) of the COVID-19 pandemic. Methods: A number of responses were implemented in ZEDS when the focus shifted to retention of study participants at the beginning of the pandemic including frequent communication with the participating clinical centers (PCCs) about remote visits, local lab work, shipping study medication, and completion of revised case report forms. Additional payments were provided to the PCCs. Remote activation of PCCs continued. Screening and enrollment visits gradually resumed when allowed. Results: Communication with PCCs increased, and average attendance at monthly coordinator teleconferences went up from 17 to 47. Remote visits peaked in April 2020, accounting for 75% (33/44) of study visits, then declined to less than 10% of study visits beginning August 2020. Overall, 97% (590/609) of study visits were completed. Only 5.5% (9/165) of study participants withdrew consent, and 2.4% (4/165) were lost to follow-up. Enrollment returned to pre-pandemic levels by September 2020. Discussion: Strong communication and unwavering commitment, combined with the technological capability for remote work, visits, and shipment of study medication, were key to the successful retention of study participants and resumption of enrollment. Conclusions: Rapid responses to challenges to trials caused by the COVID-19 pandemic can enable them to continue successfully and provide insights into the planning of future trials.
Rights/Terms© 2021 Published by Elsevier Inc.
Herpes zoster ophthalmicus
Zoster eye disease study
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/17293
- Enrollment in the Zoster Eye Disease Study.
- Authors: Cohen EJ, Jeng BH, Troxel AB, Lee M, Shakarov G, Hochman J, Gillespie C
- Issue date: 2020 Dec
- Zoster Eye Disease Study: Rationale and Design.
- Authors: Cohen EJ, Hochman JS, Troxel AB, Colby KA, Jeng BH, ZEDS Trial Research Group.
- Issue date: 2022 May 1
- Transitioning to Remote Clinic Visits in a Smoking Cessation Trial During the COVID-19 Pandemic: Mixed Methods Evaluation.
- Authors: Mahoney MC, Park E, Schlienz NJ, Duerr C, Hawk LW
- Issue date: 2021 Apr 30
- Current Practice Patterns and Opinions on the Management of Recent-Onset or Chronic Herpes Zoster Ophthalmicus of Zoster Eye Disease Study Investigators.
- Authors: Lo DM, Jeng BH, Gillespie C, Wu M, Cohen EJ
- Issue date: 2019 Jan
- International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials.
- Authors: Smeltzer MP, Scagliotti GV, Wakelee HA, Mitsudomi T, Roy UB, Clark RC, Arndt R, Pruett CD, Kelly KL, Ujhazy P, Johnson ML, Eralp Y, Barrios CH, Barlesi F, Hirsch FR, Bunn PA, International Association for the Study of Lung Cancer Coronavirus Disease 2019 and Clinical Trials Steering Committee.
- Issue date: 2022 May